Form 6-K Clearmind Medicine Inc. For: Jul 10

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of: July 2026

 

Commission file number: 001-41557

 

CLEARMIND MEDICINE INC.

(Translation of registrant’s name into English)

 

101 – 1220 West 6th Avenue

Vancouver, British Columbia

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒    Form 40-F ☐

 

 

 

CONTENTS

 

Attached hereto and incorporated herein is the Registrant’s press release issued on July 10, 2026, titled “Clearmind Medicine Responds to the U.S. Administration’s RFI for Addiction Treatment Innovations as Part of the Great American Recovery Initiative”.

 

 

EXHIBIT INDEX

 

Exhibit No.
99.1		Press release titled: “Clearmind Medicine Responds to the U.S. Administration’s RFI for Addiction Treatment Innovations as Part of the Great American Recovery Initiative”

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Clearmind Medicine, Inc.
	(Registrant)
Date: July 10, 2026	By:	/s/ Adi Zuloff-Shani
	Name:	Adi Zuloff-Shani
	Title:	Chief Executive Officer

 

 

ATTACHMENTS / EXHIBITS

PRESS RELEASE TITLED: "CLEARMIND MEDICINE RESPONDS TO THE U.S. ADMINISTRATION'S RFI FOR ADDICTION TREATMENT INNOVATIONS AS PART OF THE GREAT AMERICAN RECOVERY INITIATIVE"

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Yale approves Clearmind Medicine patient recruitment for CMND-100 trial
• How Deal IQ Grew Annual Revenue More Than 1900% Using ZoomInfo
• Clearmind Medicine to acquire 51% of EV wireless charging firm